Evolution of the diagnostic method of membranous nephropathy

[Abstract] Membranous nephropathy (MN) is one of the most common causes of adult nephrotic syndrome, and characterized by the deposition of immune complexes along the glomerular basement membrane (GBM). About 80% of cases are primary MN (PMN), and 20% are secondary MN (SMN) caused by autoimmune diseases, alloimmunity disease, infections, tumors, and contact with drugs and poisons. About one-third of patients developed spontaneous remission without treatment, one-third of patients progressed to end stage renal disease (ESRD) within 10 years, and the remaining patients showed persistent proteinuria. The traditional diagnostic method is not enough to detect and treat MN early. In order to improve the management level and clinical efficacy of MN patients, the emergence of new diagnostic tools is particularly important. The present paper summarizes the recent advances in the diagnostic approach to MN in recent years to provide a clinical reference.

[1]  K. Amann,et al.  Treatment of Membranous Nephropathy in Patients With THSD7A Antibodies Using Immunoadsorption. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  Baoli Liu,et al.  Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role , 2019, Frontiers in Immunology.

[3]  U. Specks,et al.  Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. , 2019, Journal of the American Society of Nephrology : JASN.

[4]  S. Taguchi,et al.  Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report , 2019, BMC Nephrology.

[5]  J. Lieske,et al.  Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. , 2019, Kidney international.

[6]  Shree G. Sharma,et al.  Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study , 2017, Modern Pathology.

[7]  Ajay Sharma,et al.  De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? , 2017, World journal of transplantation.

[8]  B. Liu,et al.  Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy , 2017, Scientific Reports.

[9]  Jing Xiao,et al.  Diagnostic significance of PLA2R and IgG4 in elderly patients with idiopathic membranousnephropathy , 2017 .

[10]  F. Cosio,et al.  Recurrent Membranous Nephropathy After Kidney Transplantation: Treatment and Long-Term Implications , 2016, Transplantation.

[11]  J. Farber,et al.  Membranous nephropathy in the kidney allograft , 2016, Clinical transplantation.

[12]  J. Balow,et al.  Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab , 2016, Kidney international reports.

[13]  G. Gupta,et al.  Pre‐transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post‐kidney transplantation , 2016, Clinical transplantation.

[14]  U. Maggiore,et al.  Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). , 2016, Autoimmunity reviews.

[15]  V. Jha,et al.  Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. , 2015, Kidney international.

[16]  F. Diekmann,et al.  Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy , 2015, Transplantation.

[17]  J. Wetzels,et al.  Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. , 2015, Kidney international.

[18]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2015, The New England journal of medicine.

[19]  W. Liu,et al.  The Diagnosis Accuracy of PLA2R-AB in the Diagnosis of Idiopathic Membranous Nephropathy: A Meta-Analysis , 2014, PloS one.

[20]  U. Panzer,et al.  Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[21]  M. Perazella,et al.  American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[22]  P. Walker,et al.  Phospholipase A2 Receptor (PLA2R) Staining Is Useful in the Determination of De Novo Versus Recurrent Membranous Glomerulopathy , 2013, Transplantation.

[23]  L. Beck,et al.  Membranous nephropathy: not just a disease for adults , 2013, Pediatric Nephrology.

[24]  M. Troxell,et al.  Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts. , 2011, Transplantation proceedings.

[25]  F. Cosio,et al.  Recurrent Idiopathic Membranous Nephropathy: Early Diagnosis by Protocol Biopsies and Treatment with Anti‐CD20 Monoclonal Antibodies , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  D. Hackel,et al.  Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. 1951. , 2000, Journal of the American Society of Nephrology : JASN.

[27]  M. Wagner,et al.  Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1) , 1995, Nature Genetics.

[28]  D. Salant,et al.  In situ immune complex formation and glomerular injury. , 1980, Kidney international.